Crispr Therapeutics AG (CRSP) Expected to Post Quarterly Sales of $4.00 Million

Brokerages predict that Crispr Therapeutics AG (NASDAQ:CRSP) will announce $4.00 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Crispr Therapeutics’ earnings, with the highest sales estimate coming in at $9.50 million and the lowest estimate coming in at $500,000.00. Crispr Therapeutics reported sales of $2.39 million in the same quarter last year, which indicates a positive year-over-year growth rate of 67.4%. The business is expected to announce its next quarterly earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that Crispr Therapeutics will report full year sales of $11.95 million for the current fiscal year, with estimates ranging from $3.40 million to $24.00 million. For the next fiscal year, analysts expect that the company will post sales of $55.55 million per share, with estimates ranging from $20.00 million to $91.10 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Wednesday, August 8th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.19). Crispr Therapeutics had a negative net margin of 245.57% and a negative return on equity of 39.58%. The business had revenue of $1.09 million during the quarter, compared to analysts’ expectations of $1.47 million.

Several equities research analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. Chardan Capital reissued a “buy” rating and set a $72.50 target price on shares of Crispr Therapeutics in a research note on Wednesday. BidaskClub lowered shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 26th. Finally, TheStreet lowered shares of Crispr Therapeutics from a “c” rating to a “d+” rating in a research note on Friday, May 11th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the stock. Crispr Therapeutics currently has an average rating of “Buy” and an average price target of $65.90.

In related news, Director Pablo J. Cagnoni sold 5,816 shares of the company’s stock in a transaction dated Tuesday, July 3rd. The shares were sold at an average price of $62.00, for a total transaction of $360,592.00. Following the completion of the transaction, the director now owns 5,816 shares in the company, valued at approximately $360,592. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Kurt Von Emster sold 650,000 shares of the company’s stock in a transaction dated Monday, May 14th. The stock was sold at an average price of $54.39, for a total transaction of $35,353,500.00. Following the transaction, the director now owns 5,629 shares of the company’s stock, valued at approximately $306,161.31. The disclosure for this sale can be found here. Over the last three months, insiders have sold 754,236 shares of company stock worth $41,731,001. Corporate insiders own 37.70% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund raised its position in shares of Crispr Therapeutics by 12.9% during the 1st quarter. New York State Common Retirement Fund now owns 9,691 shares of the company’s stock worth $443,000 after purchasing an additional 1,107 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Crispr Therapeutics by 66.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,827 shares of the company’s stock worth $166,000 after purchasing an additional 1,127 shares during the last quarter. SeaCrest Wealth Management LLC raised its position in shares of Crispr Therapeutics by 202.9% during the 2nd quarter. SeaCrest Wealth Management LLC now owns 2,726 shares of the company’s stock worth $160,000 after purchasing an additional 1,826 shares during the last quarter. Rockefeller Capital Management L.P. acquired a new position in shares of Crispr Therapeutics during the 2nd quarter worth about $116,000. Finally, First Mercantile Trust Co. acquired a new position in shares of Crispr Therapeutics during the 2nd quarter worth about $141,000. Hedge funds and other institutional investors own 37.65% of the company’s stock.

NASDAQ:CRSP traded down $0.84 during mid-day trading on Thursday, hitting $47.11. The company’s stock had a trading volume of 575,547 shares, compared to its average volume of 1,097,311. Crispr Therapeutics has a 1 year low of $16.16 and a 1 year high of $73.90. The firm has a market cap of $2.28 billion, a price-to-earnings ratio of -27.55 and a beta of 3.29.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Featured Story: New Google Finance Tool and Screening Stocks

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply